Treatment of overactive bladder: what is on the horizon?

作者: Alana M. Murphy , Ryan M. Krlin , Howard B. Goldman

DOI: 10.1007/S00192-012-1860-6

关键词:

摘要: There is still a need to develop additional effective and well-tolerated therapies for the treatment of overactive bladder (OAB). The purpose this review discuss alternative idiopathic OAB that employ unique mechanism action or offer novel application an existing therapy. We performed comprehensive literature identify potential future treatments OAB. use botulinumtoxin on rise FDA approval will likely be granted in future. New innovations neuromodulation hold promise less invasive more patient-controlled therapies. A number medications, such as β-adrenoreceptor agonists, medications with indications, phosphodiesterase inhibitors, have been identified In addition, drug delivery systems, vaginal inserts, are also development may provide attractive deliver proven efficacy. While conservative measures behavioral modification pelvic floor exercises remain first-line therapy OAB, anti-muscarinics mainstay medical treatment. For patients refractory traditional therapies, promising new horizon.

参考文章(50)
Ammar A Alhasso, Jayne McKinlay, Kate Patrick, Laurence Stewart, Anticholinergic drugs versus non‐drug active therapies for overactive bladder syndrome in adults Cochrane Database of Systematic Reviews. ,(2006) , 10.1002/14651858.CD003193.PUB3
James B Duthie, Michael Vincent, G Peter Herbison, David Iain Wilson, Don Wilson, Botulinum toxin injections for adults with overactive bladder syndrome Cochrane Database of Systematic Reviews. ,(2011) , 10.1002/14651858.CD005493.PUB3
Gaye Ellis, Jean Hay-Smith, G Peter Herbison, Ghulam Nabi, June D Cody, Anticholinergic drugs versus placebo for overactive bladder syndrome in adults Cochrane Database of Systematic Reviews. ,(2006) , 10.1002/14651858.CD003781.PUB2
Tara L. Frenkl, Haiyuan Zhu, Theodore Reiss, Olga Seltzer, Elizabeth Rosenberg, Stuart Green, A Multicenter, Double-Blind, Randomized, Placebo Controlled Trial of a Neurokinin-1 Receptor Antagonist for Overactive Bladder Journal of Urology. ,vol. 184, pp. 616- 622 ,(2010) , 10.1016/J.JURO.2010.03.147
Annette Schröder, Robert M Levin, Barry A Kogan, Anurag K Das, Francine Kay, Anu Mahashabde, Absorption of oxybutynin from vaginal inserts: drug blood levels and the response of the rabbit bladder☆ Urology. ,vol. 56, pp. 1063- 1067 ,(2000) , 10.1016/S0090-4295(00)00782-2
R. M. Freeman, O. Adekanmi, M. R. Waterfield, A. E. Waterfield, D. Wright, J. Zajicek, The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS) International Urogynecology Journal. ,vol. 17, pp. 636- 641 ,(2006) , 10.1007/S00192-006-0086-X
Hiroo Takeda, Yoshinobu Yamazaki, Yasuhiko Igawa, Kouichi Kaidoh, Satoshi Akahane, Hiroshi Miyata, Osamu Nishizawa, Masuo Akahane, Karl-Erik Andersson, Effects of beta(3)-adrenoceptor stimulation on prostaglandin E(2)-induced bladder hyperactivity and on the cardiovascular system in conscious rats. Neurourology and Urodynamics. ,vol. 21, pp. 558- 565 ,(2002) , 10.1002/NAU.10034